Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC).

Authors

Wolpin BM; O'Reilly EM; Ko Y; Blaszkowsky LS; Rarick MU; Rocha Lima CMS; Ritch PS; Chan E; Spratlin JL; Macarulla T

Journal of Clinical Oncology, Vol. 29, No. 15_suppl, pp. 4031–4031

American Society of Clinical Oncology (ASCO)

May 20, 2011

10.1200/jco.2011.29.15_suppl.4031

0732-183X

Elaine McWhirter